Return to the home page. top banner right
top banner bottom
Click to search.
members
Login:
Password:
Click to login
Click for Log In Help
Click to Join the Society
 
 
 
 
Click for the Heart Rhythm Foundation
Click for the IBHRE (formerly NASPExAM)
Click for Professional Education
Click for Health Policy
 
 
 
 
 
 
Click for News & Information
Click for Scientific Sessions
Click for the HRS Calendar
Click for the HeartRhythm Journal
Click for the HRS Store
Click to Find a Specialist
Click for Patient Information
Click for About HRS
Click for Membership
titlelines Drug Safety and Availability
The Heart Rhythm Society strives to keep members up to date with news about pharmaceuticals for treatment of heart rhythm disorders. The Society also maintains a strong working relationship with officials at the Food and Drug Administration (FDA) and provides input into pharmaceutical health care polices as they are being developed at the FDA.

Safety Alerts

2008
FDA Safety Alert: Risks of Combining Certain Cholesterol and AF Drugs (08/11/2008) — The FDA issued a safety alert to physicians, noting that combining certain cholesterol and atrial fibrillation medications can result in a rare, and sometimes fatal, muscle wasting condition called rhabdomyolysis. This risk is dose-related and increases when a dose of simvastatin greater than 20 mg per day is given with amiodarone. Learn more »

Recalls

2008
Digitek® Class I Recall — Potency Concern Cited (04/29/2008) — Actavis Totowa LLC is initiating a Class I nationwide recall of Digitek® (digoxin tablets, USP, all strengths) for oral use. Digitek® is used to treat heart failure and abnormal heart rhythms. Learn more »

Discontinuations

2008
Supplies of Procanbid Depleted (06/20/2008) — the Society has confirmed that supplies of PROCANBID (see below) are depleted and that there is no alternative generic drug on the US market. Physicians should contact patients on this therapy. Learn more »

King Pharmaceuticals' Procanbid to be Discontinued (01/15/2008) — Based on a business decision (not drug safety or efficacy), King Pharmaceuticals®, Inc. issued notification to physicians that PROCANBID (Procainamide Hydrochloride Extended-Release tablets, 500mg, 1000mg) will no longer be available. Learn more »

2007
Shire Announces Ethmozine will be Available until December 31, 2007 (Summer 2007) — Based on a business decision (not drug safety or efficacy), Shire issued notification to physicians Ethmozine (moricizine hydrochloride) would no longer be available as of August 28, 2007. Since discontinuation of drug therapy should be done under medical supervision and one month notice to physicians to transition patients to alternative therapies is insufficient to prevent possible harm, the Heart Rhythm Society worked with Shire Pharmaceuticals to extend the availabily for 6 months. Learn more »

Shortages

2008
Tikosyn® (Dofetilide) Shortage Update (01/21/2008) — Pfizer announced on January 18, 2008 that there is a shortage of the drug Tykosyn 0.5mg and 0.25mg . The shortage is not the result of any efficacy or safety concern with Tikosyn. An unforeseen manufacturing issue coupled with distribution regulations for Tikosyn has resulted in the product outage. The shortage was resolved as of February 1, 2008. Learn more »

Click to Print Page.Click to Email Page. Click to Contact Us.Click for the Site Map.
© Heart Rhythm Society | 1400 K St. NW, Suite 500 | Washington DC 20005 | (202)464-3400 | Fax: (202) 464-3401 | Privacy Policy